TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1888692
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 20 mg of ketanserin
Study: 1888692
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 20 mg of ketanserin
Study: 28487911
Drug: Ziyinqingre prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziyinqingre prescription (Chinese Traditional Medicine), administered twice a day for two weeks
Study: 28487911
Drug: Montelukast Sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast Sodium tablets, 10mg once a day for two weeks (Control)
Study: 24263469
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL Turkish coffee (57 mg caffeine/100 mL)
Study: 22640678
Drug: Sydney Magnoglide
Normalized name: Sydney golden wattle pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sydney Magnoglide and comprehensive fixed appliance therapy
Study: 15764779
Drug: Potassium dichromate
Normalized name: Potassium dichromate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium dichromate C30 globules, 5 globules administered twice daily at intervals of 12 h
Study: 12444480
Drug: Association between
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association between size and colour of square blocks (e.g. red = large; yellow = small)
Study: 24439651
Drug: Chamomile Extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile Extract 100 mg three times a day
Study: 24439651
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (MA) 250 mg three times a day
Study: 21623000
Drug: DMARD methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD methotrexate, sulphasalazine and hydroxychloroquine in combination (COMBO)
Study: 9605644
Drug: Granulocyte colony‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony‐stimulating factor (G‐CSF) (lenograstim; 5 microg/kg body weight per day subcutaneously)
Study: 7998486
Drug: Intravenous nimodipine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nimodipine, 2 mg per hour for 7 days
Study: 1617931
Drug: roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (150 mg b.i.d.)
Study: 2568348
Drug: D-amphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (20 mg)
Study: 26218228
Drug: Direct treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct treatment (Lidcombe Program)
Study: 26218228
Drug: Indirect treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect treatment (RESTART-DCM treatment)
Study: 18801158
Drug: Weekly chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly chloroquine (Control)
Study: 11052438
Drug: Ketamine, 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine, 0 to 5 mg/kg/h plus fentanyl, 0.1 microg/kg/min
Study: 3315778
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily for 3 days
Study: 3315778
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg in a single administration
Study: 3315778
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg in a single administration
Study: 26973701
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (310 mg choline bitartrate twice daily for 6 weeks)
Study: 16353868
Drug: Neoton in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoton in combination with ischemic training
Study: 16353868
Drug: Standard antianginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antianginal therapy
Study: 7655128
Drug: ivpb (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivpb (intravenous piggyback) infusion of tobramycin sulfate 2 mg/kg at 100 mL/h for 30 minutes
Study: 7655128
Drug: slow CRIS
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow CRIS (controlled-release infusion system) using a 20-mL vial at 60 mL/h for 1 hour
Study: 7655128
Drug: fast CRIS
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fast CRIS using a 20-mL vial at 120 mL/h for 1 hour
Study: 7565947
Drug: Fialuridine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks
Study: 2164771
Drug: Allopurinol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (50 mg qds)
Study: 2164771
Drug: DMSO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO (500 mg qds)
Study: 7028045
Drug: 5.6‐benzo‐alpha‐pyron +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6‐benzo‐alpha‐pyron + 3',4',7‐tris‐(hydroxy‐ethyl)‐rutin (coumarin + troxerutin, Venalot) at 1 mg/kg/d related to the coumarin content
Study: 14571187
Drug: Inactivated Mycobacterium
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Mycobacterium vaccae (MV) vaccine
Study: 15634953
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (CV)
Study: 21594407
Drug: Peoscopy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peoscopy and treatment of male partners, condom use for one year (Group A, n=64)
Study: 21594407
Drug: No peoscopy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No peoscopy, no treatment of male partners, condom use for one year (Group B, n=79)
Study: 21594407
Drug: Peoscopy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peoscopy and treatment of male partners, no condom use (Group C, n=40)
Study: 21594407
Drug: No peoscopy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No peoscopy, no treatment of male partners, no condom use (Group D, n=63)
Study: 27529226
Drug: Isoflavonoid‐rich herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavonoid‐rich herbal preparation (500 mg)
Study: 24619793
Drug: 1.5 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/m2 glutathione
Study: 20626402
Drug: Ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA)
Study: 20626402
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg (ROSUVA)
Study: 20626402
Drug: Ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) in patients with T2DM
Study: 20626402
Drug: Ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) in patients without T2DM
Study: 16192765
Drug: AQUAVAN Injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AQUAVAN Injection (AQ) at doses of 5, 10, 15, 20, 25, or 30 mg/kg
Study: 16192765
Drug: AQUAVAN Injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AQUAVAN Injection (AQ)
Study: 16192765
Drug: PropofolD (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PropofolD (50 mg/min)
Study: 16192765
Drug: AQUAVAN Injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AQUAVAN Injection (AQ) and PropofolD
Study: 10411363
Drug: Zofenopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril (ACE inhibitor) given within 24 hours of symptom onset
Study: 7586247
Drug: Enoxaparin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (20 mg, 40 mg, 1 mg/kg, 2 mg/kg)
Study: 25586754
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CBT + Sertraline)
Study: 21073983
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral codeine
Study: 11166973
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual comparison group
Study: 26392095
Drug: Granulocyte Colony-Stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte Colony-Stimulating Factor (G-CSF)
Study: 28661585
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla‐300) morning injection
Study: 28661585
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL (Gla‐100) evening injection
Study: 15728225
Drug: Novel six-drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel six-drug combination chemotherapy for stage III disease
Study: 15728225
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without alkylating agents for genitourinary nonbladder prostate tumors
Study: 15728225
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment strategy including selective avoidance of local therapy
Study: 15728225
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment strategy (MMT 84)
Study: 10989464
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 5 mg/m2 plus dexamethasone 2-4 mg p.o.
Study: 10989464
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron 8 mg syrup plus dexamethasone 2-4 mg p.o.
Study: 9185752
Drug: L-ornithine-L-aspartate (OA)
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate (OA) 20 g/d, infused intravenously for 4 hours over 7 consecutive days
Study: 9185752
Drug: L-ornithine-L-aspartate (OA)
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate (OA) 20 g/d
Study: 1588146
Drug: Bacterial polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial polysaccharide immune globulin (BPIG) at a dose of 0.5 ml/kg
Study: 1588146
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of diphtheria‐tetanus‐pertussis or Hib oligosaccharide‐diphtheria CRM197 conjugate vaccines
Study: 3896099
Drug: Ceruletide (cholecystokinin‐like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceruletide (cholecystokinin‐like peptide) administered intramuscularly twice a day for 4 consecutive days to schizophrenic patients.
Study: 3896099
Drug: Ceruletide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceruletide (0.3 micrograms/kg or 0.6 micrograms/kg) administered intramuscularly to normal volunteers.
Study: 3896099
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo administered intramuscularly to normal volunteers.
Study: 27539717
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir cream (test product T)
Study: 27539717
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir cream (reference product R)
Study: 20889359
Drug: Active local
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active local treatment (injection/hydroelectrophoresis)
Study: 20889359
Drug: Placebo local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo local treatment
Study: 20889359
Drug: Active local
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active local treatment (days 8 and 11) requested by placebo group
Study: 20889359
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy at 3-week follow-up
Study: 16233932
Drug: Nicotinamide (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (1200 mg m(‐2) day(‐1))
Study: 12065742
Drug: Ro 32-7315
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 32-7315 (2.5 mg/kg, i.p., twice daily)
Study: 12065742
Drug: Ro 32-7315
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 32-7315 (5 mg/kg, i.p., twice daily)
Study: 12065742
Drug: Ro 32-7315
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 32-7315 (10 mg/kg, i.p., twice daily)
Study: 12065742
Drug: Ro 32-7315
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 32-7315 (20 mg/kg, i.p., twice daily)
Study: 12065742
Drug: Ro 32-7315
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 32-7315 (450 mg, oral, single dose)
Study: 12065742
Drug: Ro 32-7315
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 32-7315 (dose-dependent)
Study: 7751529
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray 0.06%, 84 micrograms per nostril three times a day for the first 6 months, with possible dose reduction in the last 6 months.
Study: 7751529
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray 0.06%
Study: 2301192
Drug: Drug bulletin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug bulletin on renal colic treatment
Study: 2301192
Drug: Drug bulletin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug bulletin on irritable bowel syndrome (IBS) treatment
Study: 6772011
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg of elemental zinc as zinc acetate per day)
Study: 31837906
Drug: Intramuscular ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ondansetron 0.1 mg/kg plus ketamine 4 mg/kg
Study: 31837906
Drug: Ketamine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 4 mg/kg (control group)
Study: 23623914
Drug: Low-dose sodium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sodium nitrite (NaNO₂) (1.5 μmol/min for 20 min)
Study: 23623914
Drug: Low-dose sodium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sodium nitrite (NaNO₂) before ischemia
Study: 23623914
Drug: Low-dose sodium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sodium nitrite (NaNO₂) during reperfusion
Study: 18990175
Drug: Solifenacin 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5/10 mg
Study: 17158411
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise therapy (treatment group)
Study: 14574034
Drug: Oral dofetilide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dofetilide, oral bolus-flecainide, propafenone, intravenous ibutilide
Study: 14574034
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control drugs
Study: 10717333
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at intravenous doses of 1.5 mg/m(2)/day over 30 min for 5 days every 3 weeks (Arm A)
Study: 10717333
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at intravenous doses of 1.3 mg/m(2) for 5 days every 3 weeks (Arm B)
Study: 10717333
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (1.5 mg/m(2)/day)
Study: 10717333
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (1.3 mg/m(2))
Study: 1677368
Drug: Dopexamine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (high dose: 4 micrograms/kg/min)
Study: 1677368
Drug: Dopexamine (intermediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (intermediate dose: 2 micrograms/kg/min)
Study: 1677368
Drug: Dopexamine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (low dose: 1 microgram/kg/min)
Study: 6137386
Drug: Lormetazepam 0.5
Normalized name: lormetazepam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 0.5 mg
Study: 31867608
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (0.2 mJ/mm2) once a week for four weeks in addition to standard physical rehabilitation (n = 12)
Study: 31867608
Drug: Botulinum toxin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin‐A injection (0.5-2 U/kg/muscle group with maximum dose of 12 U/kg/body weight) once at entry besides standard physical rehabilitation (n = 13)
Study: 31365529
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of PDL injection
Study: 31365529
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL of PDL injection
Study: 27054365
Drug: Catheterization threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheterization threshold of 500 ml
Study: 27054365
Drug: Catheterization threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheterization threshold of 800 ml
Study: 22155768
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (qHPV vaccine; Gardasil)
Study: 18489430
Drug: Computer-assisted dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted dosage
Study: 18489430
Drug: Medical staff
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical staff dosage
Study: 12803269
Drug: metoprolol 2
Normalized name: metoprolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 2 mg
Study: 12803269
Drug: lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 20 mg
Study: 12803269
Drug: saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 2 mL
Study: 22256639
Drug: Routine complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine complex treatment
Study: 1599352
Drug: Single-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose therapy with norfloxacin (800 mg)
Study: 1599352
Drug: 3-day therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day therapy with norfloxacin (400 mg twice daily)
Study: 6327800
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (200 or 400 mg oral dose)
Study: 6327800
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (600-1000 mg/day, long-term administration)
Study: 31492603
Drug: Succinylated gelatin
Normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylated gelatin infusion (10 ml/kg)
Study: 31492603
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate infusion
Study: 31492603
Drug: Succinylated gelatin
Normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylated gelatin infusion
Study: 29557399
Drug: 4.0 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mm long implants
Study: 29557399
Drug: 10.0 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mm long implants
Study: 27144672
Drug: Post-operative RT
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative RT with TST/NMES therapy (Group II)
Study: 23234816
Drug: Chlorella group
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella group (C. vulgaris extract 1200 mg/day + metformin 750 mg/day + vitamin E 200 mg/day for 3 months)
Study: 23234816
Drug: Metformin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin group (metformin 1250 mg/day + vitamin E 200 mg/day for 3 months)
Study: 15659542
Drug: Daptomycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (4 mg/kg every 24 h intravenously for 7-14 days)
Study: 10342225
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk product containing 10(7) cfu/ml L. johnsonii La1 (group B)
Study: 10342225
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk product containing 10(6) cfu/ml L. johnsonii La1 (group C)
Study: 7875642
Drug: Nefazodone (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (50, 100, and 200 mg)
Study: 29307527
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy followed by management as usual
Study: 23596055
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin and paclitaxel with radiation
Study: 23596055
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin and radiation
Study: 23596055
Drug: Weekly chemotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly chemotherapy and radiation
Study: 23596055
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by high-dose cisplatin and radiation